Watertown, United States
Diagonal Therapeutics is a pioneering biotechnology startup founded in 2022 in the United States. It focuses on developing a new class of clustering antibody medicines through its proprietary DIAGONAL platform. This innovative approach targets the root causes of severe genetic diseases, offering potential therapies that modify disease biology and provide lasting benefits for patients with limited treatment options.
The company's lead program, DIAG723, addresses hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH), conditions with significant unmet needs. Early models have shown promising results by targeting dysregulated signaling contributing to these vascular diseases.
Diagonal Therapeutics recently secured a $125.00M Series B investment from a notable consortium of investors including Lightspeed Venture Partners, Atlas Venture, RA Capital Management, and Sanofi Ventures, among others. This financial backing supports its growing clinical pipeline, aiming to move beyond symptom relief to disease modification in challenging genetic conditions.
